Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
17 participants
OBSERVATIONAL
2018-10-01
2019-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria
NCT05017766
Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.
NCT07247942
Antibiotic Outbreak, Risk Factors for Never Event, Prediction of Inappropriate Use
NCT03489330
Reduction of Bacteriuria in Subjects Practicing Intermittent Catheterization
NCT01143116
Diagnostic Performance of Plasma Procalcitonin for the Detection of Blood Cultures Contaminations
NCT04573894
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
analysis of last resort antibiotic drug (Flucloxacillin, Imipenem, Vancomycin or Cefepim) in sweat and blood
blood draw (4.7 ml EDTA) and sweat sample taken (Macroduct Sweat Collecting System)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to understand the purpose of the study, provide signed and dated informed consent and qualify for therapeutic drug monitoring
* In-patients receiving intravenous therapy with last resort antibiotics Cefepim, Floxapen, Imipenem or Vancomycin for at least 24 hours
* Glomerular Filtration Rate \>/= 50 ml/Min
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Basel, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jens Eckstein, PD Dr. med
Role: PRINCIPAL_INVESTIGATOR
Chief Clinical Medical Office
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Basel
Basel, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Brasier N, Widmer A, Osthoff M, Mutke M, De Ieso F, Brasier-Lutz P, Wolfe L, Aithal V, Broeckling CD, Prenni J, Eckstein J. Non-invasive Drug Monitoring of beta-Lactam Antibiotics Using Sweat Analysis-A Pilot Study. Front Med (Lausanne). 2020 Aug 25;7:476. doi: 10.3389/fmed.2020.00476. eCollection 2020.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-01155; me18Eckstein
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.